474 related articles for article (PubMed ID: 26407672)
41. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
[TBL] [Abstract][Full Text] [Related]
42. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
43. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
44. Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents.
Bhagat M; Halligan S; Sofou S
Curr Pharm Biotechnol; 2012 Jun; 13(7):1306-16. PubMed ID: 22201591
[TBL] [Abstract][Full Text] [Related]
45. Gold nanoparticles: emerging paradigm for targeted drug delivery system.
Kumar A; Zhang X; Liang XJ
Biotechnol Adv; 2013; 31(5):593-606. PubMed ID: 23111203
[TBL] [Abstract][Full Text] [Related]
46. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
47. Engineered nanoparticles for drug delivery in cancer therapy.
Sun T; Zhang YS; Pang B; Hyun DC; Yang M; Xia Y
Angew Chem Int Ed Engl; 2014 Nov; 53(46):12320-64. PubMed ID: 25294565
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies.
Pietersz GA; Wang X; Yap ML; Lim B; Peter K
Nanomedicine (Lond); 2017 Aug; 12(15):1873-1889. PubMed ID: 28703636
[TBL] [Abstract][Full Text] [Related]
49. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging.
Heneweer C; Gendy SE; Peñate-Medina O
Ther Deliv; 2012 May; 3(5):645-56. PubMed ID: 22834408
[TBL] [Abstract][Full Text] [Related]
50. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
Parker CL; McSweeney MD; Lucas AT; Jacobs TM; Wadsworth D; Zamboni WC; Lai SK
Nanomedicine; 2019 Oct; 21():102076. PubMed ID: 31394261
[TBL] [Abstract][Full Text] [Related]
51. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors.
Stylianopoulos T
Ther Deliv; 2013 Apr; 4(4):421-3. PubMed ID: 23557281
[No Abstract] [Full Text] [Related]
52. Nanomedicine: the promise and challenges in cancer chemotherapy.
Naguib YW; Cui Z
Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
[No Abstract] [Full Text] [Related]
53. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic and diagnostic applications of nanoparticles.
Youns M; Hoheisel JD; Efferth T
Curr Drug Targets; 2011 Mar; 12(3):357-65. PubMed ID: 20955146
[TBL] [Abstract][Full Text] [Related]
55. Engineering the nanoparticle-protein interface for cancer therapeutics.
Saie AA; Ray M; Mahmoudi M; Rotello VM
Cancer Treat Res; 2015; 166():245-73. PubMed ID: 25895872
[TBL] [Abstract][Full Text] [Related]
56. New Strategies in Cancer Nanomedicine.
Tong R; Kohane DS
Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
[TBL] [Abstract][Full Text] [Related]
57. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura Y; Mochida A; Choyke PL; Kobayashi H
Bioconjug Chem; 2016 Oct; 27(10):2225-2238. PubMed ID: 27547843
[TBL] [Abstract][Full Text] [Related]
58. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Shi J; Xiao Z; Kamaly N; Farokhzad OC
Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
[TBL] [Abstract][Full Text] [Related]
59. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
60. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
